Artiva Biotherapeutics Inc. (ARTV) - Forward Price-to-Revenue Multiple

Brandmark of Artiva Biotherapeutics, Inc. (ARTV)

The GURU.Markets terminal displays a forward P/S multiple chart, where the metric value stands at 211.40. Artiva Biotherapeutics, Inc. (ARTV) is valued by geneticists and partners for its success in developing cellular products. Artiva Biotherapeutics, Inc. (ARTV) develops innovative NK-therapies to combat lupus and tumors. The strategy is based on the mass production of off-the-shelf drugs, which reduces costs and scales patient care.

Artiva - ARTV Market Cap to Expected Sales Ratio (period 03/26/2025 - 05/09/2025)

Metric breakdowns and analytics for Artiva (ARTV)

Summary company analysis:artivabio.com ARTV
Product sample of Artiva Biotherapeutics Inc.

Driven by inelastic demand for innovative umbilical cord blood NK cells, the forward P/S ratio reflects market expectations for the future pricing power of Artiva Biotherapeutics, Inc. (ARTV). This indicator compares current market capitalization with consensus revenue forecasts, allowing investors to track business valuation dynamics between quarterly reports. The growth of this metric confirms the market's fundamental confidence in the technology's commercialization, although it increases the asset's sensitivity to macroeconomic shocks.

Who Artiva Biotherapeutics, Inc. competes with

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple